Finerenone vs Placebo in Type 1 Diabetes and CKD

Name: Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Uploaded: 2025-11-08T05:00:00+00:00
Description: Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular morbidity and mortality and decreased quality of life. Despite gu

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Diabetes
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- Richard E. Pratley, MD
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
Diabetes
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
- Femke Rutters, MD
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
ESC Heart Failure 2025
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
- Varun Sundaram, MD, PhD
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Broadcast Replay
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
- Riccardo Maria Inciardi, MD, PhD
- Cristina Gavina, MD, PhD
- Giuseppe Galati, MD

Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston

Recommended

Title

Share on ReachMD